Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma
Background: The prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RCC (chRCC). Methods: Patients who underwent renal surgery d...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 May 2023
|
| In: |
BMC urology
Year: 2023, Volume: 23, Pages: 1-8 |
| ISSN: | 1471-2490 |
| DOI: | 10.1186/s12894-023-01263-0 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12894-023-01263-0
|
| Author Notes: | Maximilian Erlmeier, Marie Mikuteit, Stefanie Zschäbitz, Michael Autenrieth, Wilko Weichert, Arndt Hartmann, Sandra Steffens and Franziska Erlmeier |
| Summary: | Background: The prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RCC (chRCC). Methods: Patients who underwent renal surgery due to chRCC were recruited. Clinical data was retrospectively evaluated. Tumor specimen were analyzed for HGF expression by immunohistochemistry. Results: 81 chRCC patients were eligible for analysis, thereof 37 (45.7%) patients were positive for HGF. No significant associations were found for HGF expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in 5-year overall survival (OS) for patients with HGF− compared to HGF+ tumors (95.0% versus 90.9%; p = 0.410). Conclusions: In chRCC HGF expression is not associated with parameters of aggressiveness or survival. |
|---|---|
| Item Description: | Gesehen am 14.06.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2490 |
| DOI: | 10.1186/s12894-023-01263-0 |